Skip to Main Content

Author Details

Ian A Wilson
The Scripps Research Institute, USA The Skaggs Institute for Chemical Biology
1975
881
149
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36347257Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.Cell Host Microbe2023
37703367Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.Sci Adv2023
37582161Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution.Sci Signal2023
37507365Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection.Nat Commun2023
37841584Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual.iScience2023
37506693Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo.Immunity2023
37777966Widespread impact of immunoglobulin V-gene allelic polymorphisms on antibody reactivity.Cell Rep2023
38045427Structural and mechanistic insights into disease-associated endolysosomal exonucleases PLD3 and PLD4.bioRxiv2023
37540118An Ancient MHC-Linked Gene Encodes a Nonrearranging Shark Antibody, UrIg, Convergent with IgG.J Immunol2023
37534714An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity That Reverses Carfentanil-Induced Respiratory Depression.ACS Chem Neurosci2023
37722054The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2.Proc Natl Acad Sci U S A2023
37321165Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.Cell Host Microbe2023
37419097Major classes of neutralizing antibodies evaded by the SARS-CoV-2 Omicron variant.Structure2023
37384622Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies.PLoS Pathog2023
37279624Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis.Curr Opin Chem Biol2023
37044090Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.Cell Rep Med2023
37276407Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.Proc Natl Acad Sci U S A2023
37037866High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike.Nat Commun2023
37333077Widespread impact of immunoglobulin V gene allelic polymorphisms on antibody reactivity.bioRxiv2023
37198165Structural basis of epitope selectivity and potent protection from malaria by PfCSP antibody L9.Nat Commun2023
37031217Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates.Nat Commun2023
37163615Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine.Sci Transl Med2023
37162858Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift.bioRxiv2023
37461607An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity that Reverses Carfentanil-Induced Respiratory Depression.bioRxiv2023
36711543Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2.bioRxiv2023
36862518Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants.J Clin Invest2023
36175661Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection.Nat Chem Biol2023
34716683Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.Adv Sci (Weinh)2022
35808842Antigenic imprinting in SARS-CoV-2.Clin Transl Med2022
35738279Superimmunity by pan-sarbecovirus nanobodies.Cell Rep2022
35549549Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody.Proc Natl Acad Sci U S A2022
35411336Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infection.bioRxiv2022
35441178Broadly neutralizing antibodies target the coronavirus fusion peptide.bioRxiv2022
35801916Flipped over U: structural basis for dsRNA cleavage by the SARS-CoV-2 endoribonuclease.Nucleic Acids Res2022
35767670A broad and potent neutralization epitope in SARS-related coronaviruses.Proc Natl Acad Sci U S A2022
35611339Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2.bioRxiv2022
35611336Biochemical Characterization of Emerging SARS-CoV-2 Nsp15 Endoribonuclease Variants.bioRxiv2022
35344575A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum.PLoS Pathog2022
35397794A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2.Immunity2022
35599305Protective neutralizing epitopes in SARS-CoV-2.Immunol Rev2022
35594401Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.Proc Natl Acad Sci U S A2022
35654851Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.Nat Immunol2022
35445579Recent insights into the structure and function of coronavirus ribonucleases.FEBS Open Bio2022
36589893Breathing and Tilting: Mesoscale Simulations Illuminate Influenza Glycoprotein Vulnerabilities.ACS Cent Sci2022
36543789Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site.Nat Commun2022
36179689Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors.Immunity2022
35906394Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron.Commun Biol2022
36335937Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2.Cell Rep2022
35995266Biochemical Characterization of Emerging SARS-CoV-2 Nsp15 Endoribonuclease Variants.J Mol Biol2022
36203547High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike.bioRxiv2022
  • 1 - 50 of 881

Recommended Authors

Soumya G Remesh
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2014
Number of shared co-authors 5
Markus-Frederik Bohn
Department of Pharmaceutical Chemistry, University of California San Francisco
Career Start Year 2012
Number of shared co-authors 4
Goran Bajic
Icahn School of Medicine at Mount Sinai
Career Start Year 2010
Number of shared co-authors 7
Rick K Huang
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 6
Jaume Bonet
Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne
Career Start Year 2006
Number of shared co-authors 9
Brian G Pierce
University of Maryland Institute for Bioscience and Biotechnology Research
Career Start Year 2005
Number of shared co-authors 11
Nadine Czudnochowski
University of California san francisco
Career Start Year 2005
Number of shared co-authors 2
Lester G Carter
Stanford University
Career Start Year 2004
Number of shared co-authors 18
Surendra S Negi
Institute for Human Infections and Immunity, The University of Texas Medical Branch
Career Start Year 2001
Number of shared co-authors 6
Jeffrey J Gray
Johns Hopkins University
Career Start Year 2000
Number of shared co-authors 10
Udupi A Ramagopal
Poornaprajna Institute of Scientific Research (PPISR)
Career Start Year 1998
Number of shared co-authors 9
Pavel Strop
Pfizer Inc.
Career Start Year 1997
Number of shared co-authors 3
David F Burke
European Bioinformatics Institute (EMBL-EBI)
Career Start Year 1997
Number of shared co-authors 13
Jaume Pons
Pfizer Inc.
Career Start Year 1994
Number of shared co-authors 6
James C Whisstock
Monash University
Career Start Year 1994
Number of shared co-authors 3
Stephen Matthews
Imperial College London
Career Start Year 1993
Number of shared co-authors 7
Diana R Tomchick
University of Texas Southwestern Medical Center
Career Start Year 1993
Number of shared co-authors 4
Natarajan Kannan
University of Georgia
Career Start Year 1990
Number of shared co-authors 10
Miriam Eisenstein
Weizmann Institute of Science
Career Start Year 1988
Number of shared co-authors 13
Christine A Olson
University of California los angeles
Career Start Year 1988
Number of shared co-authors 3
Donald D Lorimer
Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Career Start Year 1986
Number of shared co-authors 19
Partho Ghosh
University of California
Career Start Year 1986
Number of shared co-authors 3
Mark S Johnson
Abo Akademi University
Career Start Year 1985
Number of shared co-authors 2
Randy J Read
Cambridge Institute for Medical Research, University of Cambridge
Career Start Year 1982
Number of shared co-authors 23
David S Moss
Institute of Structural and Molecular Biology, University of London
Career Start Year 1976
Number of shared co-authors 1
Tom L Blundell
Heartand Lung Research Institute, University of Cambridge
Career Start Year 1971
Number of shared co-authors 10
Michael S Chapman
University of Missouri
Career Start Year 1971
Number of shared co-authors 2
Wayne A Hendrickson
Columbia University
Career Start Year 1968
Number of shared co-authors 19
Robert M Stroud
University of California San Francisco
Career Start Year 1965
Number of shared co-authors 13
David Eisenberg
university of california los angeles
Career Start Year 1963
Number of shared co-authors 14

Collaborators

Marc-Andr?? Elsliger
Joint Center for Structural Genomics
Co-authored papers 132
Scott A Lesley
Merck & Co., Inc.
Co-authored papers 131
Adam Godzik
University of California Riverside
Co-authored papers 130
Ashley M Deacon
Accelero Biostructures Inc., USA XPose Therapeutics Inc.
Co-authored papers 127
Mitchell D Miller
Rice University
Co-authored papers 113
Lukasz Jaroszewski
University of California Riverside School of Medicine
Co-authored papers 113
Heath E Klock
Merck & Co., Inc.
Co-authored papers 105
Hsiu-Ju Chiu
Joint Center for Structural Genomics
Co-authored papers 99
Qingping Xu
Argonne National Laboratory
Co-authored papers 97
John Wooley
University of California
Co-authored papers 96
Keith O Hodgson
Stanford University
Co-authored papers 90
Henry van den Bedem
University of California San Francisco
Co-authored papers 89
Daniel McMullan
Genomics Institute of the Novartis Research Foundation
Co-authored papers 88
Andrew T Morse
Co-authored papers 79
Polat Abdubek
Regeneron Pharmaceuticals, Inc.
Co-authored papers 73
Slawomir K Grzechnik
Co-authored papers 71
Mark W Knuth
Joint Center for Structural Genomics
Co-authored papers 67
Ron Reyes
Co-authored papers 67
Herbert L Axelrod
Joint Center for Structural Genomics
Co-authored papers 61
Gye Won Han
Bridge Institute, University of Southern California
Co-authored papers 61
Edward Nigoghossian
Genomics Institute of the Novartis Research Foundation
Co-authored papers 61
Sanjay Krishna
Institute of Science, Banaras Hindu University
Co-authored papers 55
Raymond C Stevens
iHuman Institute, ShanghaiTech University
Co-authored papers 54
John P Moore
Co-authored papers 52
Christopher L Rife
The Joint Center for Structural Genomics, Stanford University
Co-authored papers 50
Peter Kuhn
University of Tubingen
Co-authored papers 49
Thomas Clayton
Celgene/Bristol-Myers Squibb Corporation
Co-authored papers 47
Kevin K Jin
Cardiovascular Institute, Stanford University School of Medicine
Co-authored papers 47
Lian Duan
Brown University
Co-authored papers 46
Julie Feuerhelm
Co-authored papers 46
Release 1.2